Cadi 05

Drug Profile

Cadi 05

Alternative Names: Cadi-05; Immuvac; Leprosy vaccine - National Institute of Immunology; Leprovac; Mycidac-C; Mycobacterium indicus pranii heat-killed - Cadila Pharmaceuticals; Mycobacterium w heat-killed - Cadila Pharmaceuticals

Latest Information Update: 30 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator National Institute of Immunology
  • Developer Cadila Pharmaceuticals
  • Class Antineoplastics; Attenuated vaccines; Bacteria; Bacterial vaccines
  • Mechanism of Action Desmocollin modulators; Immunostimulants; P38 mitogen-activated protein kinase inhibitors; Toll-like receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Leprosy; Non-small cell lung cancer
  • Phase II/III Sepsis
  • No development reported Bladder cancer; Head and neck cancer; Multiple myeloma
  • Discontinued Malignant melanoma; Prostate cancer

Most Recent Events

  • 19 Dec 2013 No development reported - Clinical for Head and neck cancer in India (Intradermal)
  • 19 Dec 2013 No development reported - Preclinical for Multiple myeloma in India (Intradermal)
  • 21 Nov 2013 Registered for Non-small cell lung cancer (with platinum doublet therapy) in India (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top